---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000053"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:17:14.505902+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada Q2 cash $376.8M; on track to dose first participant in ENTR-601-44 Phase 1 in Sept 2023

## Summary
- Cash, cash equivalents and marketable securities of $376.8M as of June 30, 2023, up from $188.7M at year-end 2022; cash runway extended through 2025.
- Collaboration revenue of $18.2M in Q2 2023 (none in prior year); net loss $25.9M vs $23.2M.
- Received MHRA and REC authorization for Phase 1 trial of ENTR-601-44 in healthy volunteers in UK; first dosing expected in September 2023 with data in H2 2024.
- IND for ENTR-601-44 on clinical hold with FDA; update expected in Q4 2023.

## SEC filing metadata
- accession: 0001689375-23-000053
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/0001689375-23-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/trda-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000053
- JSON: https://secwatch.observer/filing/0001689375-23-000053.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000053.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $25.9 million for the second quarter of 2023.
  - Period: second quarter 2023
  - Net income: Net loss was $25.9 million for the second quarter of 2023
  - Result: reported results
  source text: Net loss was $25.9 million for the second quarter of 2023, compared to a net loss of $23.2 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/0001689375-23-000053-index.htm
- Earnings Releases
  Entrada Therapeutics, Inc. reported second quarter 2023, quarter ended June 30, 2023 results: revenue 18.2 million, net income -25.9 million.
  - Period: second quarter 2023, quarter ended June 30, 2023
  - Revenue: 18.2 million
  - Net income: -25.9 million
  - Result: reported results
  source text: Collaboration revenue was $18.2 million for the second quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000053/0001689375-23-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.